Using High-Resolution Mass Spectrometry to Characterize Next- Generation Targeted LNPs

• Apply high-resolution mass spectrometry to simultaneously characterize lipid, RNA, antibody, and conjugate components within targeted LNP systems
• Quantify conjugation efficiency, assess conjugation site specificity, and investigate product-related heterogeneity impacting therapeutic performance
• Establish comprehensive analytical workflows to support discovery, process development, and CMC readiness for targeted LNP therapeutics

Speakers:

Hui Zhou

Principal Scientist,

ModeX Therapeutics